Aurora Cannabis Inc vs Amylx Pharmaceuticals Inc — how do they compare? Aurora Cannabis Inc trades at $3.67 (market cap $223.59M), while Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 11.8× Aurora Cannabis Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.
| ACB | AMLX | |
|---|---|---|
Market Cap | $223.59M | $2.64B |
Sector | Health | Health |
52-Week High | $6.23 | $24.19 |
52-Week Low | $2.58 | $7.82 |
Enterprise Value | $168.09M | $2.39B |
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $3.63, up 25.61% amid a hostile takeover bid from Curaleaf at a 45% premium. The stock shows mixed signals with a neutral technical outlook, while fundamentals reveal revenue growth to $343.29M in 2025 but a net income margin of -38.25% and negative ROE. Cash flow improved to a net positive $1.83M in 2025, though 2026 projections indicate renewed losses.
The takeover offer presents a near-term catalyst, but standalone risks persist including profitability challenges and competitive pressures. Analysts are cautious with a majority hold rating. Investors face a binary outcome: accept the premium bid or navigate ACB's volatile fundamentals.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →